PL2776032T3 - Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych - Google Patents

Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych

Info

Publication number
PL2776032T3
PL2776032T3 PL12787343T PL12787343T PL2776032T3 PL 2776032 T3 PL2776032 T3 PL 2776032T3 PL 12787343 T PL12787343 T PL 12787343T PL 12787343 T PL12787343 T PL 12787343T PL 2776032 T3 PL2776032 T3 PL 2776032T3
Authority
PL
Poland
Prior art keywords
treatment
hematologic malignancies
cxcr4 antibody
cxcr4
antibody
Prior art date
Application number
PL12787343T
Other languages
English (en)
Inventor
Michelle R. Kuhne
Chin Pan
Josephine M. Cardarelli
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL2776032T3 publication Critical patent/PL2776032T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12787343T 2011-11-09 2012-11-09 Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych PL2776032T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09
EP12787343.8A EP2776032B1 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (1)

Publication Number Publication Date
PL2776032T3 true PL2776032T3 (pl) 2019-03-29

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12787343T PL2776032T3 (pl) 2011-11-09 2012-11-09 Zastosowanie przeciwciała anty-cxcr4 w leczeniu nowotworów hematologicznych

Country Status (23)

Country Link
US (2) US10428151B2 (pl)
EP (1) EP2776032B1 (pl)
JP (1) JP6541350B2 (pl)
KR (1) KR102024957B1 (pl)
CN (1) CN104039320B (pl)
AU (1) AU2012335553B2 (pl)
BR (1) BR112014011144A2 (pl)
CA (1) CA2855155A1 (pl)
CY (1) CY1121331T1 (pl)
DK (1) DK2776032T3 (pl)
EA (1) EA026153B1 (pl)
ES (1) ES2705001T3 (pl)
HR (1) HRP20182183T1 (pl)
HU (1) HUE043001T2 (pl)
IL (1) IL232517B (pl)
LT (1) LT2776032T (pl)
MX (1) MX357100B (pl)
PL (1) PL2776032T3 (pl)
PT (1) PT2776032T (pl)
RS (1) RS58102B1 (pl)
SG (1) SG11201401386XA (pl)
SI (1) SI2776032T1 (pl)
WO (1) WO2013071068A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007320024B2 (en) * 2006-10-02 2012-11-08 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CN105899536A (zh) * 2013-11-06 2016-08-24 百时美施贵宝公司 用抗cxcr4抗体治疗c1013g/cxcr4相关的华氏巨球蛋白血症
AU2014360426B2 (en) 2013-12-06 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
EP3083678B1 (en) 2013-12-17 2019-04-03 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
WO2015118538A1 (en) 2014-02-06 2015-08-13 Yeda Research And Development Co. Ltd. Anti cd84 antibodies, compositions comprising same and uses thereof
KR20160132031A (ko) * 2014-02-19 2016-11-16 마이크로콘스탄스 차이나 아이엔씨 케모카인 수용체 대항물질 및 그것의 병용 요법
EP3242685B1 (en) * 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
KR20180063885A (ko) 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
JP6676182B2 (ja) * 2016-02-23 2020-04-08 バイオラインアールエックス・リミテッドＢｉｏＬｉｎｅＲｘ Ｌｔｄ． 急性骨髄性白血病の治療方法
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
RS62935B1 (sr) 2016-05-20 2022-03-31 Biohaven Therapeutics Ltd Primena riluzola, prolekova riluzola ili analoga riluzola sa imunoterapijama za lečenje kancera
US20190175557A1 (en) * 2016-06-16 2019-06-13 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
CN110234352A (zh) * 2017-01-31 2019-09-13 Msm蛋白质技术公司 抗cxcr4抗体
AU2018225566B2 (en) * 2017-02-21 2019-11-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11201908396PA (en) 2017-03-31 2019-10-30 Bristol Myers Squibb Co Methods of treating tumor
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
WO2019113456A1 (en) * 2017-12-08 2019-06-13 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
EP3765519B1 (en) * 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20200136454A (ko) 2018-03-27 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
JP2021519771A (ja) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2117953C (en) 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
WO2005024015A1 (en) 2003-09-04 2005-03-17 Medarex, Inc. Expression vector
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
DK2029155T3 (en) * 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
AU2007320024B2 (en) * 2006-10-02 2012-11-08 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
CN102027015A (zh) 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
WO2010043650A2 (en) 2008-10-14 2010-04-22 Ablynx Nv Amino acid sequences directed against cellular receptors for viruses and bacteria
KR101781654B1 (ko) 2009-03-12 2017-09-25 제넨테크, 인크. 조혈 악성종양의 치료를 위한 포스포이노시티드 ３-키나제 억제제 화합물 및 화학요법제의 조합물
SG10201402346UA (en) 2009-05-19 2014-10-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
US20120052097A1 (en) 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
MX2014005267A (es) 2014-07-28
EP2776032B1 (en) 2018-10-17
AU2012335553A1 (en) 2014-07-03
US20200231683A1 (en) 2020-07-23
MX357100B (es) 2018-06-26
SI2776032T1 (sl) 2018-12-31
AU2012335553B2 (en) 2017-09-21
RS58102B1 (sr) 2019-02-28
CN104039320A (zh) 2014-09-10
IL232517A0 (en) 2014-06-30
EA201490957A1 (ru) 2014-08-29
CY1121331T1 (el) 2020-05-29
US20140322208A1 (en) 2014-10-30
WO2013071068A3 (en) 2013-07-18
DK2776032T3 (en) 2019-02-04
HUE043001T2 (hu) 2019-07-29
BR112014011144A2 (pt) 2017-05-16
CN104039320B (zh) 2019-10-15
LT2776032T (lt) 2018-12-10
SG11201401386XA (en) 2014-10-30
ES2705001T3 (es) 2019-03-21
JP6541350B2 (ja) 2019-07-10
EP2776032A2 (en) 2014-09-17
KR20140093945A (ko) 2014-07-29
JP2014533279A (ja) 2014-12-11
CA2855155A1 (en) 2013-05-16
US10428151B2 (en) 2019-10-01
HRP20182183T1 (hr) 2019-02-22
IL232517B (en) 2018-05-31
EA026153B1 (ru) 2017-03-31
WO2013071068A2 (en) 2013-05-16
PT2776032T (pt) 2019-01-21
KR102024957B1 (ko) 2019-09-24

Similar Documents

Publication Publication Date Title
HRP20182183T1 (hr) Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom
HK1255608A1 (zh) 抗htra1抗體及使用方法
IL228738A0 (en) Antibodies for cancer treatment
EP2748199A4 (en) ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE
EP2760452A4 (en) METHODS OF TREATING CANCER
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof cd98
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
HK1202240A1 (en) Methods of treating cancer
HK1201855A1 (en) Antibodies and methods of treating cancer
EP2731429A4 (en) COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE
HK1201537A1 (en) Anti-kdr antibodies and methods of use -kdr
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
HK1199040A1 (en) Use of antibody
HK1190094A1 (zh) 用於治療前列腺癌的抗-α- 整聯蛋白抗體
HK1184173A1 (en) Anti-kdr antibodies and methods of use -kdr
IL232266A0 (en) Cancer treatment methods